Podcasts about Refractory

In part one of this series, Dr. Tesha Monteith and Dr. Jennifer Robblee discuss an international consensus definition for refractory migraine and why clearer criteria are needed.  Show citations: Robblee J, Minen MT, Friedman BW, Cortel-LeBlanc MA, Cortel-LeBlanc A, Orr SL. 2025 Guideline Update to Acute Treatment of Migraine for Adults in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache. 2026;66(1):53-76. doi:10.1111/head.70016 Robblee J, Khan FA, Marmura MJ, et al. Reaching International Consensus on the Definition of Refractory Migraine Using the Delphi Method. Cephalalgia. 2025;45(9):3331024251367767. doi:10.1177/03331024251367767 Show transcript:  Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. I've just been speaking with Jennifer Robblee about her exciting work defining refractory migraine with an international consensus, as well as her work with the American Headache Society on a guideline update for parental pharmacotherapies for migraine in the emergency department. Hi, Jennifer. Thanks again for coming on our Neurology Minute. Dr. Jennifer Robblee: Thank you so much for having me. I'm delighted to be here. Dr. Tesha Monteith: You've done a lot of work in the area of refractory migraine. Why don't you tell us why you felt there need to be clarification on the definition? Dr. Jennifer Robblee: Well, this is a patient population that I'm really passionate about. There's not enough research out there. We don't really know who these patients are, why they're not responding to treatment, and we don't know how to help them because we have no guidelines, obviously, since they're refractory to what we use for treating. So I thought it was really good to get an international group to standardize our definition and hopefully help move the research forward. Dr. Tesha Monteith: Why don't you tell us a little bit about the consensus definition Dr. Jennifer Robblee: So we came up with an international consensus definition for refractory migraine that was laid out the same way that migraine is, say, laid out in the ICHD-3 diagnostic manual, if you want to call it that. So we have different criteria on. So criterion A basically allowed for it to be episodic or chronic migraine. Criterion B had three subcriteria, so you needed to have at least two out of three of severe to very severe disability and/or a constant background headache and/or at least eight monthly migraine days. Criterion C was about the lack of response to treatment. And basically it says that you needed to have failure of all medication categories, and there is an extra one for an other in case any new treatments emerge before the diagnostic criteria get updated. And what we considered a, quote, unquote, failure was that you did not have a 50% improvement in monthly migraine days, or you had intolerable side effects, or you had an absolute contraindication. There is a caveat that you need to have at least four true lack of efficacies. And then the CGRP monoclonal antibody or gepant category and the onabotulinumtoxin toxin category both had to be a true lack of response. And of course, there's a criterion B to say that this should not be from another diagnosis. Dr. Tesha Monteith: Thanks so much, Jennifer.

Dr. Tesha Monteith talks with Dr. Jennifer Robblee about the latest consensus on refractory migraine, its definition, and management strategies, including new guidelines for emergency treatment.  Read the related article in Cephalalgia.  Read the related article in Headache. Disclosures can be found at Neurology.org. 

Cytomegalovirus (CMV) infection is one of the most significant infectious complications after hematopoietic cell transplant (HCT), but there have been major advances in CMV management to date. In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID, and Marcus Pereira, MD, MPH, FAST, discuss considerations for CMV treatment in HCT recipients and examine treatment options for refractory/resistant CMV. Topics include: Considerations for CMV management in HCT recipients New definitions of refractory and resistant CMV  Risk factors for refractory and resistant CMV infections Identifying drug-resistant CMV  Treatment options for refractory/resistant CMV To view the full educational program and download the accompanying slides, visit our website:https://bit.ly/4lfrDTT Presenters: Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID Professor and Chair G.P. Bodey, Sr. Distinguished Professorship in Infectious Diseases President, The International Immunocompromised Host Society (ICHS) Director, Clinical Virology Research Department of ID/IC/EH UT MD Anderson Cancer Center Houston, Texas Marcus Pereira, MD, MPH, FAST Associate Professor of Medicine Director of Clinical Services, Division of Infectious Diseases Medical Director, Transplant Infectious Disease Program Columbia University Irving Medical Center New York, New York Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Featuring an interview with Dr Sagar Lonial, including the following topics: Phase 3 randomized study evaluating teclistamab and daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib for patients with relapsed/refractory (R/R) multiple myeloma (MM) (0:00) Management of belantamab mafodotin-associated ocular events with dose modifications guided by standard assessments (3:15) Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone for transplant-ineligible patients with newly diagnosed MM (8:00) Other investigational strategies for R/R MM (12:55) CME information and select publications

Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.

What do you do when your own tongue starts "shedding" like a snake and your doctor tells you to just "eat a banana"? Imagine waking up and seeing the world through 90s TV static, while your muscles literally stretch and tear like gum when you yawn. Làyla joins the boys to break down the reality of living with Refractory Myasthenia Gravis (MG), a version of the illness so stubborn it requires constant infusions just to keep her stable. From the terrifying moment she realized her jaw was atrophying, to the bizarre neurological world of Visual Snow Syndrome, Làyla shares it all with a level of humor and confidence that is honestly infectious.You can watch this entire episode over on YouTube: https://www.youtube.com/playlist?list=PL0EVgIbBQOxtKJ4qjAlfeutzZRfCGV8nbFollow Sickboy: Instagram: https://www.instagram.com/sickboypodcastTiktok: https://www.tiktok.com/@sickboypodcastDiscord: https://discord.gg/expeUDN

David, Ryan, and Tim break down the growing uncertainty surrounding Georgia State athletics as rumors swirl about Charlie Cobb's potential exit and silence from the university fuels more questions. The guys debate what a leadership change could mean for the future, whether Jonas Hayes is officially on the hot seat, and how the basketball program's slide reflects a larger identity crisis within the department. Is this a reset moment — or is the ship still taking on water?Follow usWeb: http://stateofatlanta.comFacebook: http://facebook.com/STATEofAtlantaTwitter: http://twitter.com/STATEofAtlantaYouTube: https://www.youtube.com/@STATEofAtlantaSupport the showPatreon: http://patreon.com/STATEofAtlantaRock our swagMerch: http://merch.STATEofAtlanta.com

What do you do when your own tongue starts "shedding" like a snake and your doctor tells you to just "eat a banana"? Imagine waking up and seeing the world through 90s TV static, while your muscles literally stretch and tear like gum when you yawn. Làyla joins the boys to break down the reality of living with Refractory Myasthenia Gravis (MG), a version of the illness so stubborn it requires constant infusions just to keep her stable. From the terrifying moment she realized her jaw was atrophying, to the bizarre neurological world of Visual Snow Syndrome, Làyla shares it all with a level of humor and confidence that is honestly infectious.You can watch this entire episode over on YouTube: https://www.youtube.com/playlist?list=PL0EVgIbBQOxtKJ4qjAlfeutzZRfCGV8nbFollow Sickboy: Instagram: https://www.instagram.com/sickboypodcastTiktok: https://www.tiktok.com/@sickboypodcastDiscord: https://discord.gg/expeUDN

What are you drinking? Banter SoxFest Recap Promotions Podcast Row Reggie's After Party Recap Frank Thomas Austin Hays Jordan Hicks and David Sandlin Mike Vasil starter? Murakami and the bidet Thank Yous and GFYs

Featuring an interview with Dr Sagar Lonial, including the following topics: KLN-1010: A novel, in vivo gene therapy generating anti-BCMA chimeric antigen receptor T cells (0:00) Phase III DREAMM-7 and DREAMM-8 studies of belantamab mafodotin-based combination therapy for patients with relapsed/refractory (R/R) multiple myeloma (MM) (5:37) Effectiveness of ciltacabtagene autoleucel for patients with R/R MM (11:04) Low-dose tocilizumab for mitigation of the cytokine release syndrome associated with bispecific antibodies (16:04) Talquetamab with teclistamab for patients with R/R MM in Phase Ib of the RedirecTT-1 trial (19:24) CME information and select publications

Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.

In this episode of the YUromigospodcast, Brian Rini, Tom Powles, and Karine Tawagi discuss the complexities of immunotherapy re-challenge in bladder cancer. They explore the current landscape, including the challenges of existing data, the importance of understanding patient responses, and the potential for future research in antibody-drug conjugates (ADCs). The conversation highlights the need for more definitive studies to guide treatment decisions and improve patient outcomes.

Featuring perspectives from Dr Sagar Lonial and Dr María-Victoria Mateos, including the following topics:  Introduction (0:00) Best of ASH Multiple Myeloma (1:56) Case: A man in his late 50s with t(11;14) IgA kappa myeloma discovered during workup for new Stage IV kidney disease who has a chest wall plasmacytoma receives daratumumab with CyBorD and radiation therapy to the plasmacytoma with minimal response — Jeremy Lorber, MD (8:35) Antibody-Drug Conjugates and Other Emerging Novel Therapies for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lonial (16:58) Case: A man in his mid 80s with severe obesity and coronary artery disease, chronic heart failure and sleep apnea receives belantamab mafodotin with low-dose pomalidomide for multiregimen-relapsed myeloma — Neil Morganstein, MD (27:57) Case: A man in his mid 60s with a history of stroke with aphasia receives teclistamab for multiregimen-relapsed MM after daratumumab, proteasome inhibitors, immunomodulatory drugs and selinexor — Justin Favaro, MD, PhD (34:42) Integrating Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies into the Management of R/R MM — Dr Mateos (39:09) Case: A man in his early 70s with kappa light chain myeloma experiences complete response on cilta-cel CAR T-cell therapy with hypogammaglobulinemia requiring IVIG and develops melanoma of the abdominal wall — Bhavana (Tina) Bhatnagar, DO (52:07) Case: A man in his mid 50s with heavily relapsed MM who received multiple prior lines of therapy, including CAR T-cell therapy, receives talquetamab — Priya Rudolph, MD, PhD (55:44) CME information and select publications

Dr Sagar Lonial from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr María-Victoria Mateos from the University Hospital of Salamanca in Salamanca, Spain, discuss cases of relapsed/refractory multiple myeloma and recentresearch findings from the 2025 ASH Annual Meeting. CME information and select publications here.

In today's episode, the discussion features Lorenzo Falchi, MD, a medical oncologist/hematologist and assistant attending physician in the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, New York, who provided clinical and regulatory perspectives on the FDA approval of epcoritamab-bysp (Epkinly) in combination with rituximab (Rituxan) and lenalidomide (Revlimid) for relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy. The approval was supported by primary results from the randomized phase 3 EPCORE FL-1 trial (NCT05409066).In this exclusive interview, Dr Falchi discussed why this approval is clinically meaningful—establishing a chemotherapy-free triplet that significantly improves outcomes over the long-standing rituximab/lenalidomide backbone in the second-line setting and beyond—and reviewed practical considerations that inform real-world uptake of the regimen, including outpatient administration feasibility and mitigation of bispecific antibody–associated toxicities, such as cytokine release syndrome. He also placed EPCORE FL-1 in the broader epcoritamab development program, referencing supportive experience with the phase 1/2 EPCORE NHL-2 trial (NCT04663347) and ongoing efforts to move bispecific antibody–based regimens earlier in the treatment paradigm through the phase 3 EPCORE FL-2 trial (NCT06191744).any of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

In today's episode, the discussion features Surbhi Sidana, MD, an associate professor of medicine (blood and marrow transplantation and cellular therapy) and leader of the Myeloma CAR-T/Immunotherapy Program at Stanford University/Stanford Medicine, as well as a member of the Stanford Cancer Institute, who provided clinical and regulatory perspectives on the FDA approval of belantamab mafodotin-blmf (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The approval was supported by findings from the phase 3 DREAMM-7 trial (NCT04246047).

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net.Today on the emDOCs cast, Jess Pelletier and Brit Long cover benzodiazepine-refractory status epilepticus. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play 

In this episode of The Medicine Grand Rounders, we're joined by Dr. Wilson Tang, research director and staff cardiologist in the section of heart failure and cardiac transplantation, who delves into the cardiorenal physiology, decongestion strategies and future therapies. Moderated by: Faysal Massad

Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy

Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Lorenzo Falchi and Robert Levy on their latest papers published in Blood Journal. Dr. Falchi discusses his work on an open-label, multicenter phase 1b/2 study evaluating fixed-duration epcoritamab with rituximab and lenalidomide in 108 patients with relapsed or refractory follicular lymphoma. Dr. Levy shares his work on demonstrating that in vivo expansion of Tregs in recipients prior to transplant is possible by activating TNFRSF25 (also known as death receptor 3) in combination with low-dose interleukin-2 in preclinical models. Both papers showed impressive and promising results for the treatment of lymphoma and GVHD.Featured ArticlesFixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular LymphomaPre-transplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues ameliorating GVHD post-HSCT

Please visit answersincme.com/CAZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology answers the most commonly asked questions from clinicians about the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) with antibody–drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Identify patients with R/R DLBCL who may benefit from ADC therapy in the third-line or later setting; Interpret current evidence to inform selection of ADC therapies for patients with R/R DLBCL in the third-line or later setting; and Discuss strategies to optimize the use of ADC therapies for patients with R/R DLBCL, particularly in the community setting.

Dr. Alison Christy and Dr. Matthew Ryan Woodward discuss the complexities of status epilepticus, focusing on its definitions, the transition to refractory and super-refractory states, and the implications for treatment.  Show citation: Woodward MR, Brown JP, Kittner SJ, et al. Super-Refractory Status Epilepticus Diagnosis, Management, and Prognostication: An International Survey Study. Neurol Clin Pract. 2025;15(5):e200520. doi:10.1212/CPJ.0000000000200520  

In the second episode of this three-part series, we delve into the science behind Refractory Chronic Cough (RCC), focusing on the role of neuronal hypersensitivity and how the cough reflex becomes dysregulated.1 Join leading experts as they explain the neurobiology of RCC, discuss the latest research, and share practical insights for identifying RCC in clinical practice.

Dr. Alison Christy talks with Dr. Matthew Ryan Woodward about the complexities of status epilepticus, focusing on its definitions, the transition to refractory and super-refractory states, and the implications for treatment.  Read the related article in Neurology® Clinical Practice.  Disclosures can be found at Neurology.org. 

In this episode, Dr. Rena Malik, MD speaks with Dr. Jim Pfaus about the science behind semen retention, psychological arousal, and the myths surrounding sexual behaviors such as the nofap movement. Together, they explore the neurobiology of orgasm, the impact of compulsive sexual behavior, and how factors like guilt, anticipation, and mental health contribute to sexual well-being. Listeners will gain a deeper understanding of the real physiological and psychological processes influencing sexual satisfaction and self-control. Become a Member to Receive Exclusive Content: renamalik.supercast.com Schedule an appointment with me: https://www.renamalikmd.com/appointments ▶️Chapters: 00:00 Semen retention claims 01:10 Delayed gratification effects 02:40 Orgasms without ejaculation 04:20 Loss of interest with long delays 05:14 Compulsivity and mental clarity 07:16 Myths about porn and orgasm 08:09 Dopamine, reward, and guilt 11:41 Refractory period differences 13:58 Compulsion, anxiety, depression 15:43 Compulsion vs addiction 20:25 Tiger Woods example Let's Connect!: WEBSITE: http://www.renamalikmd.com YOUTUBE: https://www.youtube.com/@RenaMalikMD INSTAGRAM: http://www.instagram.com/RenaMalikMD TWITTER: http://twitter.com/RenaMalikMD FACEBOOK: https://www.facebook.com/RenaMalikMD/ LINKEDIN: https://www.linkedin.com/in/renadmalik PINTEREST: https://www.pinterest.com/renamalikmd/ TIKTOK: https://www.tiktok.com/RenaMalikMD ------------------------------------------------------ DISCLAIMER: This podcast is purely educational and does not constitute medical advice. The content of this podcast is my personal opinion, and not that of my employer(s). Use of this information is at your own risk. Rena Malik, M.D. will not assume any liability for any direct or indirect losses or damages that may result from the use of information contained in this podcast including but not limited to economic loss, injury, illness or death. Learn more about your ad choices. Visit megaphone.fm/adchoices

Refractory epilepsy in veterinary medicine refers to a condition in which an animal with epilepsy fails to attain satisfactory seizure control or suffers intolerable side effects despite appropriate therapy with conventional anti-seizure drugs. Refractory epilepsy is an important problem in small animal practice as it occurs in approximately one-third of dogs with epilepsy. In this session, we discuss the reasons underlying this challenging situation in an individual patient and how this knowledge can help us develop improved therapeutic strategies.

Prof Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Joseph Mikhael from City of Hope Cancer Center in Phoenix, Arizona, and Dr Noopur Raje from Massachusetts General Hospital in Boston discuss recent updates on available and novel treatment strategies for relapsed/refractory multiple myeloma.  CE information and select publications here.

Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos, Dr Hans Lee, and Dr Noopur Raje, moderated by Dr Joseph Mikhael, including the following topics:  Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Raje (3:17) Integrating Bispecific Antibodies into the Management of R/R MM — Dr Lee (20:38) Potential Role of Antibody-Drug Conjugates and Cereblon E3 Ligase Modulators in Therapy for MM — Prof Dimopoulos (40:37) CE information and select publications

Severe refractory asthma, which affects approximately 1% to 5% of patients with asthma, is associated with increased morbidity and mortality. Author Juan Carlos Cardet, MD, MPH, of the University of South Florida joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the management of patients with severe refractory asthma, including first-line medications and biologics. Related Content: Management of Severe Refractory Asthma

In het zonnestelsel-in-wording HOPS-315 kunnen astronomen zien hoe ons eigen zonnestelsel er zo'n 4.6 miljard jaar geleden uit moet hebben gezien. En u hoort in deze aflevering hoe u een royale selectie van de muziek van deze podcast als album kunt kopen op Bandcamp.Witnessing a solar system's dawn, for the 1st time:https://earthsky.org/space/solar-systems-dawn-hops-315-silicon-monoxide/Refractory solid condensation detected in an embedded protoplanetary disk:https://www.eso.org/public/archives/releases/sciencepapers/eso2512/eso2512a.pdfHL Tauri (foto van protoplanetaire schijf):https://en.m.wikipedia.org/wiki/HL_TauriSteun de show en koop de muziek van deze podcast:https://henszimmermanaudio.bandcamp.com/album/really-slow-tapesDe Zimmerman en Space podcast is gelicenseerd onder een Creative Commons CC0 1.0 licentie.http://creativecommons.org/publicdomain/zero/1.0

Osteosarcoma Webinar Series: Amy Armstrong, MD, a pediatric oncologist at Siteman Kids, joins us on OsteoBites to discuss an open-label, cohort-sequential dose-escalation and dose-confirmation Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma and osteosarcoma. She will review background, patient selection, treatment plan and study calendar for this clinical trial.Dr. Amy Armstrong is a pediatric oncologist who directs the Solid Tumor Program at Siteman Kids, affiliated with St. Louis Children's Hospital, as well as co-directs the Adolescent and Young Adult Sarcoma Program in collaboration with Siteman Kids and Siteman Cancer Center. She is an Associate Professor of Pediatrics at Washington University in St. Louis and has research interests in Neurofibromatosis Type 1-related plexiform neurofibromas, renal tumors, and sarcomas found most commonly in the adolescent and young adult population. Dr. Armstrong serves as site Principal Investigator for the Children's Oncology Group, Neurofibromatosis Clinical Trials Consortium and National Pediatric Cancer Foundation and is invested in conducting and developing clinical trials to serve a diverse range of solid tumors in both the upfront and relapsed setting.

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents:- What are "CAR T" and "bispecific antibodies"?- What are the approved agents?- Selection of one therapy over another- Side effect profiles**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Send us a textSteve plays a bunch of BAD games and Trav...doesn't. Lots of good games coming out to look forward to. Kergon brings home the gold. Top 5 Death/Game Over Screens in Gaming (Potomax).Our next episode is Live on Twitch, September 27th at Noon Eastern. Games this episodeTrails in the Sky 1st Chapter (PlayStation 5, Switch, PC) – September 19Baby Steps (PlayStation 5, PC) – September 23Hades II (Switch 2, Switch, PC) – September 25Silent Hill f (PlayStation 5, Xbox Series X/S, PC) – September 25Sonic Racing: CrossWorlds (PlayStation 5, Xbox Series X/S, PlayStation 4, Xbox One, Switch, PC) – September 25Pac-Man World 2 Re-Pac (PlayStation 5, Xbox Series X/S, Switch 2, PlayStation 4, Xbox One, Switch, PC) – September 26Hotel Barcelona (PlayStation 5, Xbox Series X/S, PC) – September 26DE-EXIT: Eternal MattersHeartwormParanormal Activity: The Lost SoulThe King of Route 66 (PS2)Shinobi: Art of Vengeance (Switch)SilksongThe Midnight WalkSonic Adventure 2 (DreamCast)Find more shows at polymedianetwork.com, BlueSky: Trav, Steve, Polykill, Polymedia twitch.tv/blinkoom, Send us an email polykillpodcast@gmail.com, Check out our patreon at Patreon.com/polykill How to be a Polykiller: Beat a game, take a screenshot, post it on BlueSky or Polymedia Discord, use #justbeatit, write a review and be sure to include @Polykill. Beat the most, become Polykiller. Beat any, have your Skeet potentially read on the show! Check out the Bonus Beats episodes on Patreon for more beat-skeet coverage!

Adam's Paternity Leave is near its end, but while we still have a few weeks left of it, let's look at the first of a pair of episodes (we'll pick up the second installment next week) featuring a key Emmy presenter from last night. A few resourceful new Munchies have figured out a work-around where you can join as a free member and upgrade from there to a paid account which charges you for one month and unlocks the back catalog behind the respective tier of the paywall. After that first payment, you won't be charged again until we're dropping new content (which we'll warn everyone is coming), so if you want more of this it can be had, along with access to the fully uncut episodes from 100 to present and Movie Club episodes.Hot on the heels of an episode that nearly broke our rating scale, the Munchie Boys watched Part 1 of a two-parter featuring Ray Romano's kooky brother Robert from the hit turn-of-the-century sitcom for olds, Everybody Loves Raymond. Fans of that show will remember that the actor in question, Brad Garrett, is really, REALLY tall. This causes the kind of continuity problems that only SVU can create. We're obviously talking about complex genital geometry problems. We would, of course, be remiss if our discussion stayed on topic, so expect to hear about Chinese New Year, more car talk from Josh, Rikers Island, and Predator.Sources:A Look Inside Rikers - NY TimesMusic:Divorcio Suave - “Munchy Business”Thanks to our gracious Munchies on Patreon: Jeremy S, Jaclyn O, Amy Z, Diana R, Tony B, Barry W, Drew D, Nicky R, Stuart, Jacqi B, Natalie T, Robyn S, Amy A, Sean M, Jay S, Briley O, Asteria K, Suzanne B, Tim Y, John P, John W, Elia S, Rebecca B, Lily, Sarah L, Melsa A, Alyssa C, Johnathon M, Tiffany C, Brian B, Kate K, Whitney C, Alex, Jannicke HS, Roni C, Erin M, Florina C, Melissa H, and Olivia - y'all are the best!Be a Munchie, too! Support us on Patreon: patreon.com/munchmybensonBe sure to check out our other podcast diving into long unseen films of our guests' youth: Unkind Rewind at our website or on YouTube, Apple Podcasts, or wherever you listen to podcastsFollow us on: BlueSky, Facebook, Instagram, Threads, and Reddit (Adam's Twitter/BlueSky and Josh's BlueSky/Letterboxd/Substack)Join our Discord: Munch Casts ServerCheck out Munch Merch: Munch Merch at ZazzleCheck out our guest appearances:Both of us on: FMWL Pod (1st Time & 2nd Time), Storytellers from Ratchet Book Club, Chick-Lit at the Movies talking about The Thin Man, and last but not least on the seminal L&O podcast …These Are Their Stories (Adam and Josh).Josh discussing Jackie Brown with the fine folks at Movie Night Extravaganza, debating the Greatest Detectives in TV History on The Great Pop Culture Debate Podcast, and talking SVU/OC and Psych (five eps in all) on Jacked Up Review Show.Visit Our Website: Munch My BensonEmail the podcast: munchmybenson@gmail.comThe Next New Episode Once We're Back from Adam's Paternity Leave Will Be: Season 16, Episode 14 "Intimidation Game"Become a supporter of this podcast: https://www.spreaker.com/podcast/munch-my-benson-a-law-order-svu-podcast--5685940/support.

This week, we shift our focus to talking about relapsed/refractory follicular lymphoma. In this episode, we will specifically discuss treatment options other than cellular therapy, which will be an upcoming episode. If you have not done so, we highly recommend listening to part 1 and part 2 of this follicular lymphoma series so that you can better follow this week's conversation!Episode contents:- What is the role of rituximab maintenance therapy? - What does surveillance after therapy look like? - What are options for treatment of patients who have relapsed follicular lymphoma? **** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this episode of The Poison Lab, host Ryan Feldman is joined by Dr. Joe Kennedy, medical toxicologist at the University of Vermont and consultant for the Northern New England Poison Center. Together they work through real poisoning cases to sharpen toxic differentials, sum up practical resuscitation priorities, and connect first-principles pharmacology to bedside decisions. They also answer listener questions on THAM vs bicarbonate, when to dialyze even with “normal” kidneys, and why rattlesnake antivenom costs so much—plus the real-world logistics of sourcing exotic antivenoms in the U.S.Dr. Kennedy and Ryan discuss the topics below. Looking for timestamps? Join the subscribed feed!Case set #1: Shock with hyperglycemia, big pupils, and probably NOT what you think it is. Case set #2: Massive bleeding after gas-station “herbal” productsCase set #3: Refractory wide-complex rhythms in a teen overdoseCase set #4: Sudden collapse at a hog farm- (SPOLIER) Recent outbreak of deaths as related to case 4Want the cases summarized and sent to you so you can come up with your differential before the show? SIGN UP FOR THE NEWS LETTER! Listener Q&ATHAM vs bicarbonate (closed vs open buffering; “breathe for bicarb, tinkle for THAM”)Why dialyze if the kidneys work? (EXTRIP-style thinking, gradients, and properties)Snake antivenom pricing & how zoos help hospitals obtain non-U.S. antivenomsCall outs from the showNACCT Abstracts!Clover coagulopathy!THAM VS BICARB ElectrolytesPotato quality video of dialysis from RyanArticle on snake antivenom costing >200,000 for one patientArticle on exotic antivenom procurementCase report Ryan published on treating blue Indonesian pit viperSupport the showReview the show where ever your listeningGet Messages from Toxo (Join the Newsletter!)Join as a supporting memberAd free episodesBonus content and early accessDiscounts and give aways on GOTA PICCEM Mushroom card gameThe GOTTA PICCEM Poisonous Mushroom Game! Tox trinkets (Rep the show at home!)Reach the showEmail: Toxtalk1@gmail.comMore Show ResourcesRyan's Medical Games and Resources

Send comments and feedbackIn a retrospective study of 31 patients with highly refractory epilepsy, 29% had more than a 50% reduction in seizures for at least 12 months after being treated with immunotherapy. Three of these patients became seizure free. Other than a trend toward a diagnosis of focal epilepsy, researchers did not identify any specific features predictive of treatment response. Sharp Waves spoke with the first author about the study and its implications.The study was published in Epilepsia in April 2025. Sharp Waves episodes are meant for informational purposes only, and not as clinical or medical advice.Let us know how we're doing: podcast@ilae.org.The International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Instagram, and LinkedIn.

In this podcast, expert faculty Atul Humar, MD, FRCP (C), and Camille Kotton, MD, FIDSA, FAST, take a deep dive into complex clinical scenarios and explore designing antiviral regimens for refractory CMV infections to minimize antiviral toxicities and maximize efficacy. Topics covered include:Management for suspected drug-resistant CMV infection Illustrative patient cases Gene mutations in CMV  Presenters:Atul Humar, MD, FRCPC, FASTProfessorDepartment of MedicineUniversity of TorontoEaton Family Chair in Transplant Infectious DiseasesAjmera Transplant CentreUniversity Health NetworkToronto, CanadaCamille Kotton, MD, FIDSA, FAST Clinical Director, Transplant and Immunocompromised Host Infectious DiseasesInfectious Diseases DivisionMass General Brigham Endowed Cancer Chair IVMassachusetts General HospitalAssociate Professor, Harvard Medical SchoolBoston, MassachusettsLink to full program:https://bit.ly/4lOa2kAGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:  Introduction (0:00) A Farmer with Myeloma; Is Myeloma the New Chronic Myeloid Leukemia? (2:06) Clinical Trials (12:34) Chimeric Antigen Receptor Therapy (16:11) Bispecific Antibodies (21:38) Antibody-Drug Conjugates; a Patient on Belantamab Mafodotin for 3 Years (30:45) Treatment Options for Relapsed Disease (40:46) Neuropathy (44:43) Alternative Therapies (48:36) 164 Questions (53:20) CME information and select publications

Dr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. CME information and select publications here.

Learn to appropriately modify antiviral therapy in solid organ transplant recipients with treatment-refractory cytomegalovirus (CMV) infections with expert faculty, Atul Humar, MD, FRCP (C). Topics covered include:Comparisons of available CMV antiviral therapies:Ganciclovir, valganciclovir, foscarnet, cidofovir, maribavirConsiderations for renal function monitoring with ganciclovir and valganciclovirA treatment algorithm for relapsed/refractory CMVThe latest clinical trial data and guideline recommendationsPresenter:Atul Humar, MD, FRCP (C) ProfessorDepartment of MedicineUniversity of TorontoEaton Family Chair in Transplant Infectious DiseasesAjmera Transplant CentreUniversity Health NetworkToronto, CanadaLink to full program:https://bit.ly/4lOa2kAGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify

Tune in to learn the fundamentals for timely identification of refractory cytomegalovirus (CMV) infections following solid organ transplantation from expert faculty, Camille Kotton, MD, FIDSA, FAST. Topics covered include:Direct and indirect effects of CMV infectionRisk factors for resistant/refractory CMVDefining resistant/refractory CMVPresenter:Camille Kotton, MD, FIDSA, FAST Clinical Director, Transplant and Immunocompromised Host Infectious DiseasesInfectious Diseases DivisionMass General Brigham Endowed Cancer Chair IVMassachusetts General HospitalAssociate Professor, Harvard Medical SchoolBoston, MassachusettsLink to full program:http://bit.ly/4lOa2kAGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In today's episode, we spoke with Nisha Joseph, MD, and Hans Lee, MD, about the FDA's accelerated approval of linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Joseph is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia. Lee is the director of Myeloma Research at the Sarah Cannon Research Institute in Nashville, Tennessee.  In our conversation, Drs Lee and Joseph discussed the significance of this approval, key data from the pivotal phase 1/2 LINKER-MM1 trial (NCT03761108), and where linvoseltamab fits into the relapsed/refractory myeloma treatment paradigm alongside other approved agents. 

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:  Introduction: Multiple Myeloma — 2005 to 2025 (0:00) Questions from the Beginning (7:53) Choosing Options (13:54) Clinical Trials (18:03) Neuropathy (23:55) Chimeric Antigen Receptor (CAR) T-Cell Therapy (28:40) Bispecific Antibodies (35:18) Antibody-Drug Conjugates (43:08) Interacting with the Oncology Team (51:47) Other Questions (57:30) Educational and presenter information

For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia, to discuss the patient experience associated with the diagnosis and treatment of relapsed/refractory multiple myeloma. Educational and faculty information here.

This week, Chad & Cy are once again joined by the most infamous guest in Middle Of Somewhere history... Mike Cronin (@BoneSnake3)! ⁠⁠Head on over to Chad's YouTube page to watch this episode!⁠⁠ This episode is brought to you by BetterHelp! Give online therapy a try at ⁠betterhelp.com/SOMEWHERE⁠ and get on your way to being your best self. --- Follow us on ⁠⁠Instagram⁠⁠! Chad Daniels (⁠⁠@ThatChadDaniels⁠⁠) is a Dad, Comedian, and pancake lover. With over 750 million streams of his 5 albums to date, his audio plays are in the 99th percentile in comedy and music on Pandora alone, averaging over 1MM per week. Chad's previous album, Footprints on the Moon was the most streamed comedy album of 2017, and he has 6 late-night appearances and a Comedy Central Half Hour under his belt. Cy Amundson (⁠⁠@CyAmundson⁠⁠) With appearances on Conan, Adam Devine's House Party, and Comedy Central's This is Not Happening, Cy Amundson is fast-proving himself in the world of standup comedy. After cutting his teeth at Acme Comedy Company in Minneapolis, has since appeared on Family Guy and American Dad and as a host on ESPN's SportsCenter on Snapchat. Learn more about your ad choices. Visit podcastchoices.com/adchoices